Answers are grounded in this paper and cite their sources.
Chikungunya virus (CHIKV) is an alphavirus that has spread globally in the last twenty years. Although mortality is rather low, infection can result in debilitating arthralgia that can persist for years. Unfortunately, no treatments or preventive vaccines are currently licensed against CHIKV infections. However, a large range of promising preclinical and clinical vaccine candidates have been developed during recent years. This review will give an introduction into the biology of CHIKV and the immune responses that are induced by infection, and will summarize CHIKV vaccine development.
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: